State Street Corp cut its stake in Heron Therapeutics, Inc. (NASDAQ:HRTX) by 2.8% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,737,309 shares of the biotechnology company’s stock after selling 50,369 shares during the period. State Street Corp’s holdings in Heron Therapeutics were worth $24,063,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently bought and sold shares of the stock. Janus Henderson Group PLC acquired a new stake in Heron Therapeutics in the second quarter valued at $78,134,000. Vanguard Group Inc. raised its holdings in Heron Therapeutics by 11.8% in the second quarter. Vanguard Group Inc. now owns 2,096,465 shares of the biotechnology company’s stock valued at $29,036,000 after acquiring an additional 221,362 shares in the last quarter. Rubric Capital Management LP raised its holdings in Heron Therapeutics by 6.3% in the second quarter. Rubric Capital Management LP now owns 1,700,000 shares of the biotechnology company’s stock valued at $23,545,000 after acquiring an additional 100,000 shares in the last quarter. Balyasny Asset Management LLC raised its holdings in Heron Therapeutics by 2.1% in the second quarter. Balyasny Asset Management LLC now owns 1,221,403 shares of the biotechnology company’s stock valued at $16,916,000 after acquiring an additional 24,688 shares in the last quarter. Finally, Northern Trust Corp raised its holdings in Heron Therapeutics by 10.0% in the second quarter. Northern Trust Corp now owns 556,407 shares of the biotechnology company’s stock valued at $7,706,000 after acquiring an additional 50,354 shares in the last quarter.
TRADEMARK VIOLATION NOTICE: “Heron Therapeutics, Inc. (HRTX) Position Cut by State Street Corp” was reported by Week Herald and is the sole property of of Week Herald. If you are accessing this piece on another publication, it was illegally copied and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://weekherald.com/2017/11/15/heron-therapeutics-inc-hrtx-position-cut-by-state-street-corp.html.
Several research firms recently issued reports on HRTX. Zacks Investment Research raised shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, November 8th. Noble Financial reaffirmed a “buy” rating and issued a $24.00 price target on shares of Heron Therapeutics in a report on Friday, October 6th. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and issued a $27.00 price target on shares of Heron Therapeutics in a report on Friday, November 10th. BidaskClub raised shares of Heron Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 26th. Finally, Cowen and Company set a $40.00 price target on shares of Heron Therapeutics and gave the company a “buy” rating in a report on Thursday, August 3rd. One research analyst has rated the stock with a sell rating, two have issued a hold rating and ten have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $28.36.
Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) opened at $15.45 on Wednesday. Heron Therapeutics, Inc. has a twelve month low of $12.21 and a twelve month high of $20.85. The company has a debt-to-equity ratio of 0.62, a quick ratio of 2.02 and a current ratio of 2.12.
Heron Therapeutics (NASDAQ:HRTX) last issued its earnings results on Monday, November 6th. The biotechnology company reported ($0.77) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.87) by $0.10. The company had revenue of $8.57 million for the quarter, compared to analysts’ expectations of $8.12 million. Heron Therapeutics had a negative net margin of 831.89% and a negative return on equity of 385.11%. sell-side analysts expect that Heron Therapeutics, Inc. will post -3.41 earnings per share for the current year.
About Heron Therapeutics
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.